|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | C12N 15/09 | (2006.01) |
| C07K 16/28 | (2006.01) | ||
| C12N 5/00 | (2006.01) | ||
| C12P 21/08 | (2006.01) | ||
| C12Q 1/02 | (2006.01) |
| (11) | Number of the document | 2439273 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11178191.0 |
| Date of filing the European patent application | 2006-05-02 | |
| (97) | Date of publication of the European application | 2012-04-11 |
| (45) | Date of publication and mention of the grant of the patent | 2019-02-27 |
| (46) | Date of publication of the claims translation | 2019-05-10 |
| (30) | Number | Date | Country code |
| 679466 P | 2005-05-09 | US | |
| 738434 P | 2005-11-21 | US | |
| 748919 P | 2005-12-08 | US |
| (72) |
Srinivasan, Mohan, US
Wang, Changyu, US
Selby, Mark, J., US
Chen, Bing, US
Cardarelli, Josephine, M., US
Korman, Alan, J., US
Huang, Haichun, US
|
| (73) |
ONO PHARMACEUTICAL CO., LTD.,
1-5, Doshomachi 2-chome Chuo-ku, Osaka-shi, Osaka 541-8526,
JP
E. R. Squibb & Sons, L.L.C., Route 206 & Province Line Road, Princeton, NJ 08540, US |
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(PD-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-PD-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais |
| Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| Payment date | Validity (years) | Amount | |
| 2019-04-25 | 14 | 289.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2020-04-19 |